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Background: Pseudomonas aeruginosa populations within the cystic fibrosis lung exhibit extensive phenotypic and
genetic diversification. The resultant population diversity is thought to be crucial to the persistence of infection and
may underpin the progression of disease. However, because cystic fibrosis lungs represent ecologically complex
and hostile environments, the selective forces driving this diversification in vivo remain unclear. We took an
experimental evolution approach to test the hypothesis that sub-inhibitory antibiotics can drive diversification of
P. aeruginosa populations. Replicate populations of P. aeruginosa LESB58 were cultured for seven days in artificial
sputum medium with and without sub-inhibitory concentrations of various clinically relevant antibiotics. We then
characterised diversification with respect to 13 phenotypic and genotypic characteristics.
Results: We observed that higher population diversity evolved in the presence of azithromycin, ceftazidime or
colistin relative to antibiotic-free controls. Divergence occurred due to alterations in antimicrobial susceptibility
profiles following exposure to azithromycin, ceftazidime and colistin. Alterations in colony morphology and
pyocyanin production were observed following exposure to ceftazidime and colistin only. Diversification was not
observed in the presence of meropenem.
Conclusions: Our study indicates that certain antibiotics can promote population diversification when present in
sub-inhibitory concentrations. Hence, the choice of antibiotic may have previously unforeseen implications for the
development of P. aeruginosa infections in the lungs of cystic fibrosis patients.
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The mutations that lead to the genetic disorder cystic
fibrosis (CF) predispose patients to chronic bacterial lung
infections, particularly with the opportunist Pseudomonas
aeruginosa [1]. Once established, these chronic bacterial
infections are virtually impossible to eradicate and lead
to a decline in pulmonary function, reduction in quality
of life and premature death [2-4]. During chronic lung
infections in CF patients, P. aeruginosa populations
accumulate mutations generating considerable population* Correspondence: C.Winstanley@liv.ac.uk
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reproduction in any medium, provided the ordiversity, leading to both genotypic and phenotypic varia-
tions [5-9]. This diversification process can lead to various
phenotypic sub-types co-existing in the same population,
varying in characteristics such as colony morphology,
including mucoid conversion, the inactivation of quorum-
sensing (QS) and other virulence-associated traits, hyper-
mutation, loss of the O-antigen components of the
lipopolysaccharide, loss of motility, resistance to antibiotics
and changes in nutritional requirements [7,10-15]. In a
previous study, we analysed 1720 isolates of the Liverpool
Epidemic Strain (LES) of P. aeruginosa from 43 sputum
samples obtained from 10 chronically infected adult CF
patients [9]. Following the characterisation of the isolates for
15 traits, 398 haplotypes (defined as a specific combinationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fied. The majority of phenotypic diversity occurred within
individual CF patients. We further showed that this
diversity was highly dynamic, with a rapid turnover of
subtypes over time.
Certain phenotypic changes, such as the evolution of
hypermutability and mucoidy, are commonly reported in
CF isolates of P. aeruginosa and, therefore, suggest
conserved evolutionary pathways of adaptation [16,17].
The CF lung presents a highly complex environment that
is viscous, spatially heterogeneous and compartmentalized.
Moreover, it houses a rich microbiota of coexisting species,
which may compete for resources or cause P. aeruginosa
mortality (e.g., bacterial killing via bacteriocins or bacterio-
phages). Furthermore, the CF lung environment exposes
colonising bacteria to physiologically stressful conditions,
including host immune responses, oxidative stress and
antibiotic treatment [18,19]. Thus it has been hypothesised
that phenotypic diversification allows P. aeruginosa to
adapt to the hostile environment of the CF lung thereby
enabling long-term persistence. Moreover, it has been
argued that such diversification leads to either increased
or reduced virulence [16,20] and could therefore be crucial
to understanding disease progression and treatment.
While all of these facets of the CF lung environment
could potentially play a role in mediating the diversifica-
tion of P. aeruginosa, it is not possible to disentangle or
determine the relative importance of these selective forces
in vivo. A powerful approach to understanding the contri-
bution of particular selective forces to driving bacterial
diversification is through experimental evolution, whereby
replicate populations are exposed to defined selective
conditions in the laboratory.
CF patients are typically subject to extended antibiotic
regimes, but the drugs do not necessarily reach the
entire lung at inhibitory concentrations [21]. Therefore,
sub-inhibitory antibiotic exposure could be one factor
that promotes P. aeruginosa diversification in the CF lung.
Consequently, a better understanding of the responses of
P. aeruginosa populations to these sub-inhibitory concen-
trations of antibiotics in the CF lung would allow clinicians
to make better informed choices of antibiotic regimes.
Although it is likely that most CF patients acquire
P. aeruginosa infections from diverse environmental
reservoirs and thus carry their own unrelated strains,
several multidrug-resistant “epidemic” strains capable of
patient to patient transmission have been identified [22].
The LES is the most widespread transmissible strain of
P. aeruginosa in the UK [23], and has also been reported
in North America [24]. It has been detected in as many
as 79% of adult CF patients in a Liverpool CF centre
[25]. The high prevalence of LES in CF patients is a concern,
given that chronic LES infection has been associated
with a greater deterioration in pulmonary function andnutritional state [26] and increased antibiotic resistance
[27]. In this study, we analysed P. aeruginosa LES popula-
tions in an artificial sputum medium (ASM) model that
mimics CF sputum in terms of composition. Various groups
have utilised ASM models to study, for example, gene
expression patterns and the effects of bacteriophages
[28-30]. P. aeruginosa, when cultured in ASM, forms
biofilms and diversifies with respect to phenotype, in a
manner that resembles behaviour in the CF lung [30].
We hypothesise that exposure to sub-inhibitory concen-
trations of antibiotics will drive bacterial diversification,
possibly through a combination of antibiotic-induced mu-
tagenesis or through the regulation of gene transcription
[31-36]. Consequently, the objective of this study was
to test the hypothesis that exposure to sub-inhibitory
concentrations of antibiotics has a role to play in promoting
P. aeruginosa population diversification during growth in
an ASM model.
Results
Sub-inhibitory antibiotics promote diversification of
P. aeruginosa LESB58
The emergence of novel haplotypes was observed in all
culture conditions, but the presence of sub-inhibitory con-
centrations of certain antibiotics significantly increased
both the number of novel haplotypes (p <0.01, LRT = 48.8,
d.f. = 6) and the haplotype diversity found within popula-
tions (p < 0.01, F6,14 = 5.90) relative to control populations
(Figures 1 and 2). However, some antibiotics contributed
to this diversity more than others. Diversification was
highest in the presence of ceftazidime and colisitin (total
of 29 and 25 novel haplotypes, respectively) compared to
azithromycin (total of 12 novel haplotypes), tobramycin
(total of 12 novel haplotypes) and meropenem (total of 7
novel haplotypes; Figures 1 and 2). Furthermore, based on
mean antibiotic resistance across the antibiotics tested,
the Brown-Forsythe-Levene test of equality of variances
between 7 groups gave a test statistic of F(6,833) = 15.3,
p < 0.001. Exposure to ceftazidime and colistin gave a
high variance, and the differences between means are
statistically significant (F = 61.5, P < 0.001). There was no
significant difference in the colony forming unit (CFU)
values between the populations exposed to antibiotics in
ASM and in populations exposed to ASM alone. ASM
appears to generate variation in bacterial numbers among
replicates.
Haplotype properties differ between different antibiotic
exposures
Diversification of P. aeruginosa LESB58 in ASM cultured
with and without the various antibiotics was observed only
with respect to colony morphology, pyocyanin production
and antibiotic susceptibilities (Table 1). The culture of
LESB58 in ASM with sub-inhibitory concentrations of
Figure 1 Diversification of LESB58 grown in the presence (closed circles) or absence (open circles) of antibiotics. Forty isolates of LESB58
from each culture were characterised using 13 traits (colony morphology, pyocyanin production, hypermutability, auxotrophy, susceptibility to 6
antibiotics and the presence/absence of 3 genomic regions). Therefore, 120 isolates were analysed for each experimental and control group
across the 3 replicate populations. Isolates with different traits were identified as being a different haplotype. 3 replicate populations from each of
the following treatments were analysed: LB (18 hours), ASM, and ASM with ceftazidime (+ CAZ), ASM with colistin (+CT), ASM with meropenem
(+MEM), ASM with tobramycin (+TOBI), ASM with azithromycin (+AZT). (A) Number of novel haplotypes found within each replicate population.
(B) Haplotype diversity found within each replicate population, defined as the probability of two randomly picked haplotypes being non-identical.
(C) The colony forming units found within each replicate population following culture. P-values represent comparisons with ASM alone.
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susceptibilities, changes in colony morphology and a
loss of pyocyanin production (Table 1). LESB58 cultured in
the presence of these antibiotics, generated more isolates
that were outside the normal range of the antibiotic sensi-
tivity profiles of LESB58 controls (Figure 3). In addition,
exposure to azithromycin and tobramycin promoted
increased cross-resistance to other antibiotics (Table 1,
Figure 3). There was no variation in the auxotrophic
phenotype in the isolates analysed in all experimental and
control groups (LESB58 has an auxotrophic phenotype).
The populations exposed to meropenem exhibited no
clear phenotypic diversification (Table 1 and Figure 2).Furthermore, there was no variation in the carriage of
the LES prophage 5, LES prophage 2 and LES Genomic
Island (GI)-5 in the isolates analysed (all isolates tested
contained these genetic elements). None of the tested
isolates grown in ASM (from both treatment and control
groups) displayed the hypermutable phenotype. The only
hypermutable isolate detected in this study was generated
following growth in Luria Bertani (LB) for 18 hours
(Figure 2 and Table 1). Although diversification occurred
with respect to only a few of the phenotypic properties
tested, the proportions of the isolates exhibiting these traits
varied considerably between treatment groups (Figure 1).
The proportions of these phenotypic changes accounted
Figure 2 Population structure of LESB58 grown in ASM with and without sub-inhibitory concentrations of antibiotics. Each population
structure of LESB58 was calculated using 13 traits (colony morphology, pyocyanin production, hypermutability, auxotrophy, susceptibility to 6
antibiotics and the presence/absence of 3 genomic regions) for the total 120 isolates by the eBurst algorithm. Each dot (and subsequent
number) represents one novel haplotype, with dot size reflecting abundance. The larger the dot size, the more abundant that novel haplotype
was in the 120 isolates that we characterised. Haplotypes designated with the number 1 represent isolates with the same characteristics as the P.
aeruginosa LESB58 wild-type. The haplotypes representing isolates that had a straw-coloured colony morphology are circled in red; the
haplotypes representing isolates that did not over-produce pyocyanin are circled in blue; and the one isolate that was hypermutable is circled in
green. The remaining haplotypes differed in their antibiotic susceptibility profiles (All groups: n = 120).
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seen in the numbers of mutant haplotypes (Figure 1).
Hierarchical analysis of variance indicated that the majority
(77%) of diversity was distributed between isolates within
populations, rather than the same traits systematically
apportioned between replicate populations or between
treatments (Table 2).
Discussion
Although it is known that the phenotypic and genotypic
characteristics of P. aeruginosa populations within the
CF lung fluctuate over time [9,16], the factors that areresponsible for this diversification are not fully understood.
When P. aeruginosa LESB58 was grown in ASM with and
without sub-inhibitory concentrations of antibiotics, we
observed differential effects of antibiotics commonly used
to treat CF patients on the diversity of LESB58 populations
in the ASM model. In particular, increased levels of
phenotypic diversification occurred in LESB58 popula-
tions grown in ASM when sub-inhibitory concentrations
of colistin, ceftazidime and azithromycin were present.
However, extensive diversification of the P. aeruginosa
populations was not seen in the presence of sub-inhibitory
concentrations of meropenem.
Table 1 Number of isolates in each group (total of 120) exhibiting each of the traits measured
Colony morphology Virulence Mutations Outside normal range of antimicrobials susceptibility
Culture Green non-mucoid Straw non-mucoid Pyocyanin Hypermutability Ceftazidime Ciprofloxacin Tobramycin Meropenem Colistin Tazobactam/piperacillin
ASM 120 0 117 0 3 0 19 0 2 8
ASM + CAZ 110 10 92 0 16 19 20 18 10 11
ASM + CT 113 7 84 0 17 37 29 15 7 9
ASM + AZT 120 0 120 0 0 16 34 0 4 4
ASM +MEM 120 0 118 0 1 8 4 0 0 1
ASM + TOBI 118 2 119 0 1 24 69 3 22 1
LB (18 hours) 120 0 120 1 0 0 0 0 0 0
Isolates that were characterized as being outside the normal range of antimicrobial susceptibility typically observed in LESB58, included isolates that had either an increased or reduced susceptibility to the antibiotic



















Figure 3 Variations in zones of inhibition within LESB58 populations. The 120 LESB58 isolates obtained from the triplicate ASM cultures
were assessed for susceptibility to six commonly used antibiotics (ceftazidime, ciprofloxacin, colistin, meropenem, tazobactam/piperacillin and
tobramycin). Boxplots showing the range in the diameter of the zones of inhibition to these antibiotics are presented. 1. LB (18 hours) 2. ASM 3.
ASM with ceftazidime 4. ASM with colistin 5. ASM with meropenem 6. ASM with tobramycin 7. ASM with azithromycin 8. Normal range of LESB58
(Groups 1–8: n = 120). The red line represents the cut-off for the sensitivity of P. aeruginosa to the antibiotics tested, in accordance with the
guidelines of Andrews and Howe [37]. The values above the red line denote a higher sensitivity to antibiotics and the values below the line
denote a higher resistance.
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inhibitory concentrations of antibiotics could potentially
enhance bacterial diversification. One potential mechanism
could involve the antibiotics inducing mutagenesis withinbacterial populations, causing variation and/or promoting
the hypermutability phenotype [31-34]. A second potential
mechanism could involve the antibiotics acting as signal-
ling molecules, altering the QS systems within bacterial
Table 2 Hierarchical analysis of variance (σ2) for diversity
Sigma %
Variations between treatment 0.03 6.18
Variations between samples within treatment 0.09 16.42
Variations within samples 0.42 77.40
Total variations 0.54 100.00
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and diversification [35,36,38]. Antibiotic exposure has
been shown to induce mutagenesis by triggering the SOS
response and thus increasing the expression of error-prone
DNA polymerases, which could give rise to diversity within
bacterial populations [31-34]. It is possible that ceftazidime
induced mutagenesis in the LESB58 populations through
the induction of the SOS response. It has been suggested
that this increase in mutagenesis is an adaptive strategy
that favours the acquisition of antimicrobial resistance
and survival in harsh environments [33,39]. However, it
has been argued that the generation of genetic variants
within the CF lung does not require the SOS response,
and that starvation and oxidative stress caused by antibiotic
exposure can promote diversity within P. aeruginosa
biofilms [31,40-42].
The hypermutable phenotype occurs as a consequence
of defects in error avoidance or DNA repair genes, typically
termed anti-mutator genes [43]. It has been suggested
that hypermutability, promoted by extrinsic and intrinsic
factors, is the driver of P. aeruginosa adaptation and
survival in the CF lung [44,45]. Although phenotypic
diversification of LESB58 was observed following culture
in ASM, especially when sub-inhibitory concentrations
of colisitin, ceftazidime or azithromycin were present,
no hypermutable isolates were detected. In our previous
study using LES isolates from multiple CF patients, we
found hypermutable sub-types but only at low frequency
[9]. In this study we found no evidence that hypermutability
was driving this diversification and adaptation process.
This supports work by Ciofu et al. [10] who found that
the hypermutability phenotype was not essential for the
acquisition of mucoidy and loss of QS. Other studies have
also suggested that spontaneous mutation and mutator
strains are not required to produce genetic variants in
populations of P. aeruginosa within the CF lung [40,46].
It has been shown that sub-inhibitory concentrations of
antibiotics can act as signalling molecules that regulate
bacterial gene transcription, physiology and virulence
[36,38,47-51]. In particular, tobramycin, colistin and
azithromycin at sub-inhibitory concentrations have been
shown to modulate the QS networks in bacterial popula-
tions [35,36,38]. These antibiotics are commonly used to
treat CF patients and, therefore, the signalling activities
of these antibiotics could increase bacterial fitness for
survival in the harsh environment of the CF lung [38],suggesting that the classical view of antibiotics acting
only to reduce bacterial fitness and virulence is not always
the case. In the current study, across all the ASM cultures,
no single dominant phenotypic variant emerged. Some
patterns in the diversification process were evident.
For example, isolates lacking the pyocyanin production
phenotype occurred following culture in ASM with
ceftazidime or colistin. However this was only evident
in two out of the three biological replicates (ASM +
Ceftazidime: 27.5% and 40% of the isolates; ASM + Co-
listin: 42.5% and 40% of the isolates), highlighting the
variability between replicates. A previous study by
Cummins et al. [38] has shown that sub-inhibitory
concentrations of colisitin actually increases pyocyanin
production. Pyocyanin production is regulated by QS,
which relies upon small diffusible signal molecules
interacting with transcriptional activators to couple
gene expression with cell population density. Although
QS-deficiency is a common feature amongst P. aeruginosa
CF isolates [16,52,53], QS regulates a number of factors of
relevance to CF, including pyocyanin and LasA production
[54]. Our previous studies suggested that LES populations
in CF comprise a mixture of QS-positive and QS-deficient
bacteria [7,9,54], which is what we have observed in this
study in ASM. The QS-deficient populations could benefit
at the cost of QS-positive populations.
The main phenotypic variations involved changes in col-
ony morphology, pyocyanin production and antimicrobial
susceptibilities. A high diversity in the antimicrobial
susceptibility profiles of CF isolates within adult sputum
samples has been demonstrated previously [9], highlighting
the limitations of performing antimicrobial susceptibility
tests on a single isolate from a CF patient sputum sample.
It was also shown that using one antibiotic could lead to
enhanced resistance to a different, unrelated antibiotic [9].
A similar pattern was observed in this study, when expos-
ure to one antibiotic altered the antibiotic susceptibility
profiles to unrelated antibiotics. In particular, exposure to
azithromycin, tobramycin or ceftazidime led to an increase
in resistance to tazobactam/piperacillin. This could have
serious clinical consequences for the CF patient, in terms
of the generation of antimicrobial resistant P. aeruginosa
populations, because CF patients are regularly exposed
to a number of different antibiotics. In our study, the
presence of meropenem had a weaker effect on diversifica-
tion compared to the other antibiotics, despite having a
similar mechanism of action to ceftazidime. However, it is
possible that cell death was occurring in these populations,
since the numbers of cells obtained following culture were
generally lower. This is despite the meropenem concentra-
tion in ASM being 8-fold less than the minimum inhibitory
concentration of this antibiotic. Therefore, the appar-
ent reduction in diversity could be attributed to the
populations exhibiting cell death. This suggests that
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(eg. meropenem) rather than others. It would also be
interesting to analyse combinations of two antibiotics, since
it is often the case that dual therapy is used clinically. The
identification of individual mutations within the LESB58
populations to explain the changes in individual phenotypic
traits would have been beyond the scope of this work.
Conclusions
This study suggests that the exposure to sub-inhibitory
concentrations of certain antibiotics can drive phenotypic
diversification of P. aeruginosa populations in the ASM
model. This may help to explain the observed diversifica-
tion of P. aeruginosa in natural CF lung infections, although
other factors such as the host immune response, other
members of the microflora, or bacteriophages may also
contribute. Understanding P. aeruginosa diversification
in the CF lung could alter the way we control these
infections, in particular during the early stages. Diversifi-
cation of the P. aeruginosa populations in the CF lung,
and the emergence of phenotypes such as mucoidy, are
signs of adaptation leading to a chronic infection state.
Diversification may also lead to enhanced antimicrobial
resistance. Antibiotics that do not cause extensive diversi-
fication might be utilised to prevent diversification, and
possibly slow down the development of a chronic infection
state. Therefore, being able to delay, control or possibly
reduce diversification could be advantageous for the CF
patient. This could also be achieved by using antibiotics
that permeate the lung and the bacterial biofilms better to
achieve inhibitory concentrations, but it could also be
important to choose antibiotics that do not promote
diversification. Hence a better understanding of the
differential effects of various antibiotics on diversification
of P. aeruginosa populations could provide valuable
information to help clinicians choose the best antibiotics
for CF patients.
Methods
ASM preparation and culture conditions
The ASM was prepared following the protocol of
Sriramulu et al. [30] and Kirchner et al. [55]. ASM
contains mucin from porcine stomach (Sigma-Aldrich,
Gillingham, UK), DNA (Sigma-Aldrich), the iron-chelator
diethylene triamine pentaacetic acid (Sigma-Aldrich), NaCl
(Sigma-Aldrich), KCl (Sigma-Aldrich), egg yolk emulsion
(Sigma-Aldrich) and all essential and non-essential
amino acids (Fisher Scientific, Loughborough, UK and
Sigma-Aldrich) at concentrations found in an average CF
patient [30]. A single colony of the genome-sequenced P.
aeruginosa CF isolate LESB58 [56] was used to inoculate
LB broth and cultured for 18 h at 37°C and 200 rpm. The
overnight culture was diluted in fresh LB to an A600nm of
0.05 (± 0.01) and 300 μl of this diluted LESB58 culturewas added to 30 ml ASM. The ASM cultures were
incubated at 37°C for 7 days at 50 rpm. Where appropri-
ate, sub-inhibitory concentrations of either ceftazidime
(0.125 μg/ml), colistin (1 μg/ml), meropenem (2 μg/ml),
tobramycin (2 μg/ml) or azithromycin (0.25 μg/ml) were
added to the ASM. The minimum inhibitory concentra-
tions were of ceftazidime 8 μg/ml, tobramycin 16 μg/ml,
ciprofloxacin 168 μg/ml, colistin 8 μg/ml, meropenem
16 μg/ml, and azithromycin 16 μg/ml. Sub-inhibitory
concentrations were determined by testing the growth of
P. aeruginosa LESB58 exposed to a dilution series of these
antibiotics in ASM. The antibiotics were then tested at 8,
16, 32, 64-fold below the minimum inhibitory concentra-
tion, and the antibiotic concentration used was the highest
that did not affect the growth rate in ASM. Therefore,
the sub-inhibitory concentration of each antibiotic was
the highest concentration of antibiotic that still allowed
culture absorbance readings similar to that of the negative
control (LESB58 grown in the absence of antibiotics). In
addition, as a control LESB58 was cultured in ASM
without antibiotics for 7 days. The experimental design
for analysing P. aeruginosa LESB58 populations cultured
in ASM, with and without antibiotics, is shown in Figure 4.
Visible biofilms had formed by day 2 of LESB58 culture in
ASM and increased in size by day 3. There were no visible
changes in the biofilm mass between day 3 and day 7 of
incubation. There were no visible differences between the
biofilms formed in the ASM in the presence of the various
antibiotics, compared to the biofilms formed in ASM
without antibiotics. Following the 7 day incubation, the
ASM was treated with Sputasol (Oxoid, Basingstoke, UK)
in a ratio of 1:1 and incubated for 30 min at 200 rpm and
at 37°C. Sputasol has been used in previous studies to
liquefy the biofilms formed in ASM and to release the P.
aeruginosa [9,55,57]. The sputasol-treated cultures were
serially diluted and grown on Columbia agar (Oxoid).
Columbia agar has been used in previous studies to cul-
ture P. aeruginosa [7,57]. Additionally, the widely-used
Miles and Misra method was performed to determine the
numbers of bacterial CFU/ml [58]. Following overnight
growth, 40 isolates per 30 ml volume of ASM were ran-
domly selected. The 40 isolates selected from each
30 ml volume of ASM did not represent technical repli-
cates. The experiments involving culture of LESB58 in
ASM (with or without antibiotics), and the subsequent
analysis, were performed in triplicate. Therefore, 120
isolates from each experimental and ASM control group
were analysed using various phenotypic and genotypic
tests. Furthermore, to demonstrate the absence of exten-
sive diversity in the LESB58 populations that seeded the
ASM cultures, we assessed the phenotypic and genotypic
properties of LESB58 following culture in LB for 18 hours
(40 isolates were selected from three LESB58 cultures
in LB).
Figure 4 Summary of experimental design. The figure describes the steps involved in processing of the LESB58 populations cultured in ASM,
with or without antibiotics, and the phenotypic and genotypic tests performed on individual isolates.
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The earliest available LES isolate, LESB58 (from 1988), has
been genome sequenced and it contains 5 GIs (including
LESGI-5) and 5 complete prophages (including LES
prophages 2 and 5) within its accessory genome [56].
PCR assays were used to screen for LES prophage 5,
LES prophage 2 and LESGI-5 (Table 3). PCR amplifica-
tions were carried out in a volume of 25 μl. Each reac-
tion contained 1.25 U GoTaq polymerase (Promega,
Southampton, UK), 1x Green GoTaq Flexi buffer (Promega),
300 nM of each oligonucleotide primer (Sigma-Genosys,
Haverhill, UK; Table 3), 2.5 mM MgCl2 (Promega),
100 mM nucleotides (dATP, dCTP, dGTP, dTTP; Bioline)
and 1 μl DNA from boiled suspensions of colonies. Amp-
lification was carried out for 30 cycles of 95°C (1 min), the
annealing temperature (2 min) and 72°C (2 min), after
which, a final extension step of 72°C for 10 min was carried
out. Electrophoresis of PCR products was performed using
a 1% (w/v) agarose gel at 100 V for 1 h.
Phenotypic tests
The phenotypic tests used are those described previously
for our study of isolates from CF patients [9]. Colony
morphology was assessed on Columbia agar. AuxotrophyTable 3 Oligonucleotide primers used in this study
Name Sequence (5′-3′) Size (bp) Annealing te
LESD3cIF ATGAAAAAGCCCGTAAGA 490 55
LESD3cIR GCCATTCCCGCTTAAAAG
LES1F TCGGCGTAATGTCCTCTA 392 68
LES1R TGAAGCCGACGATGGAAG
PS1F ACAGAATATTCGAAGCAG 338 58
PS1R ACAAGAGCCTAACACCACwas investigated by testing the ability of isolates to grow
on glucose M9 media. Hypermutability was assessed by
determining the spontaneous mutation rates on LB
agar containing rifampicin (Sigma-Aldrich; 300 mg/ml)
following overnight growth in LB broth, as previously
described [45]. Overproduction of pyocyanin was detected
and measured using pre-determined cut-off values [60].
Isolates were classified as overproducers of pyocyanin when
the culture supernatant had an absorbance greater than
0.1 at 695 nm, following overnight growth in 5 ml LB
broth at 200 rpm. The sensitivity and resistance profiles of
the individual isolates to antibiotics commonly used to
manage CF infections (ceftazidime, colistin, meropenem,
tazobactam/piperacillin, ciprofloxacin and tobramycin; all
from Oxoid) were determined using the disk diffusion
method. The sizes of the zones of inhibition (mm) were
recorded, and compared to the zone sizes generated
from replicates of P. aeruginosa LESB58 used as controls
(n = 120). Zones sizes that were outside the range (either
above or below) that was observed for the replicates of
LESB58, were reported as being different from the
founder (LESB58). The following amounts of antibiotics
were present in the disks: 85 mg tazobactam/piperacillin,
10 mg meropenem, 10 mg tobramycin, 5 mg ciprofloxacin,mperature (°C) Target gene Reference
LES prophage 5 cI repressor gene [13]
LES prophage 2 [59]
LES genomic island-5 [59]
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mended by British Society for Antimicrobial Chemothe-
rapy guidelines [37].Defining a haplotype
In this study, a haplotype was defined as a specific com-
bination of phenotypic and genotypic traits. Diversity was
displayed using the eBurst algorithm [61], which produces
a diagrammatical representation of the diversity within a
bacterial population, and can be used to show where the
founder haplotype (LESB58) diversifies to produce a cluster
of closely related haplotypes. To obtain an eBurst diagram,
each phenotypic and genotypic trait was assigned a nu-
merical code and, therefore, each haplotype had a specific
combination of numerical values [9]. The eBurst algorithm
was used to compare the numerical profiles of each
haplotype, in order to determine relatedness between
haplotypes. Isolates characterised as haplotype number
one had the same trait values as P. aeruginosa LESB58
(“The Founder”). These traits were a green non-mucoid
colony morphology on Columbia agar, over-production
of pyocyanin, resistance to ceftazidime and an auxotrophic,
non-hypermutable phenotype. Haplotypes one position
away from the founding haplotype on the eBurst diagrams
differed in one trait from LESB58, and isolates two
positions away from the founding haplotype on the eBurst
diagram differed in two traits. This method of analysing
P. aeruginosa haplotypes has been published previously
by Mowat et al. [9].Statistical analysis
A generalised linear model with a negative binomial error
distribution was used to test whether the number of novel
haplotypes was differed between ASM and ASM plus
antibiotic treatments, with significance assessed using a
likelihood ratio test. Haplotype diversity was calculated
as the probability of two randomly picked clones being
the same haplotype based on the haplotype frequencies
within a sample (equivalent to the Simpson’s Index) and
analysed in a linear model following a logistic transform.
Hierarchical analysis of variance was performed using
the ade4 package in R [62] in order to estimate the
population differentiation between treatment groups,
between populations within treatment groups and between
clones within populations.
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